Biovica International AB BIOVIC B
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 1.68
- Day Range
- SEK 1.55–1.85
- 52-Week Range
- SEK 1.19–5.18
- Bid/Ask
- SEK 1.58 / SEK 1.60
- Market Cap
- SEK 134.83 Mil
- Volume/Avg
- 404,389 / 221,336
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 13.86
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Biovica International AB is a biotech company. It develops and commercializes blood-based diagnostic tests with biomarkers that improve monitoring and evaluation of modern cancer treatments. Through collaboration with world- leading cancer institutes and pharmaceutical companies, it promotes the trend in healthcare for personalized treatment, with a primary focus on patient survival and benefits to society. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 37
- Website
- http://www.biovica.com
Valuation
|
Metric
|
BIOVIC B
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.04 |
Price/Sales | 13.86 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BIOVIC B
|
|---|---|
Quick Ratio | 7.10 |
Current Ratio | 7.27 |
Interest Coverage | — |
Quick Ratio
BIOVIC B
Profitability
|
Metric
|
BIOVIC B
|
|---|---|
Return on Assets (Normalized) | −79.52% |
Return on Equity (Normalized) | −96.36% |
Return on Invested Capital (Normalized) | −90.97% |
Return on Assets
BIOVIC B
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lwkpgxynnl | Vhg | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Sqczkgfc | Ckyhhk | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rjswvdgl | Hkdntjq | $99.5 Bil | |
MRNA
| Moderna Inc | Wmxbylsf | Qgm | $38.8 Bil | |
ARGX
| argenx SE ADR | Cgcnwmzd | Bhsr | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Zbpmbmch | Mnxnf | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xdtpjvlx | Vywvxfn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jrndwdvx | Mzvnyb | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qtjmnybcs | Fbxnkc | $12.5 Bil | |
INCY
| Incyte Corp | Tbyzmzty | Ckjzvc | $11.6 Bil |